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 INTRODUCTION 
 Schistosomiasis (bilharzia) is a neglected tropical disease 
caused by trematode parasitic worms of the genus  Schistosoma . 
Approximately 207 million persons are infected worldwide, 1 
which leads to the loss of approximately 1.53 million disability-
adjusted life years. 2 The greatest burden of disease is found in 
sub-Saharan Africa, 3 where intestinal schistosomiasis, caused 
by infection with  Schistosoma mansoni and to a lesser extent 
by  S. intercalatum or  S. guineensis , occurs .
 Pathologic changes associated with intestinal schistosomi-
asis are predominately brought about by detrimental immu-
nologic responses to eggs, produced by female worms, which 
become trapped in host tissues. Migration of eggs through the 
intestinal wall, for example, causes perforations and stimulates 
an initial eosinophilic inflammatory reaction in the mucosa. 
Granulomas eventually form around the eggs if they are 
not voided and fibrosis ensues to form large non-malignant 
masses often known as bilharziomas. 4– 7 Common symptoms 
and pathologic changes range from anemia, abdominal pain, 
and diarrhea with or without blood, to pseudopolyps, microul-
cerations, and obstruction of the colon. 2, 5, 8– 12 Frequently eggs 
pass by the portal vein into the liver and become lodged in the 
periportal spaces, which leads to local inflammatory reactions 
that can result in hepato-splenomegaly, portal hypertension, 
and gastrointestinal varices. 2, 4, 8, 13, 14 Ultimately bleeding from 
esophageal varices may occur, which can be fatal with hemate-
mesis as an obvious visual sign. 15 
 National programs to control schistosomiasis have been 
conducted in Brazil and China for more than 20 years but have 
only recently been established in sub-Saharan Africa. These 
programs are based on regular mass distribution of the anthel-
minthic drug praziquantel, and their main aim is the control 
of schistosomiasis-associated morbidity rather than infections 
 per se . 16 School-aged children have been particularly targeted 
for mass chemotherapy because they generally show the high-
est infection intensities (as assessed by egg counts in stool) 
and were thought to be the group most likely to respond to 
praziquantel treatment with subsequent reductions in mor-
bidity. 17 However, recent work has indicated that pre-school 
children are also at risk of infection and can benefit from 
chemotherapy. 18, 19 
 The repertoire of simple, inexpensive, and non-invasive 
methods to measure the intestinal morbidity associated with 
schistosomiasis is rather limited, and new assays are urgently 
needed to evaluate the impact of control programs (through 
assessment of morbidity pre-treatment and post-treatment) 
and to determine the overall disease burden associated with 
schistosomiasis. 11, 15, 20 Clinical signs and symptoms such as ane-
mia, abdominal pain, and diarrhea are not necessarily specific 
to schistosomiasis but associations can be strong in high-trans-
mission areas. 21 Intestinal granulomas, fibrosis, and ulceration 
are only detectable through invasive methods such as rectal 
biopsy or sigmoidoscopy, which require hospitalization and 
cannot be applied on a large scale or in the field. 4, 20 
 Recent work indicates that fecal levels of eosinophil cat-
ionic protein and eosinophil protein X may prove to be use-
ful markers for intestinal morbidity. However, the assay is 
relatively complex and requires freezing of stool extracts and 
transport to a well-equipped laboratory. 22 In contrast, a num-
ber of field-applicable tools exist for assessment for hepatic 
and splenic pathology, which develop later in the progression 
of the disease. These tools include clinical palpation of the 
liver and spleen and ultrasonography by using portable ultra-
sound machines. 14, 20 However, the search for direct markers of 
bowel morbidity continues. 
 Calprotectin, a multimeric complex of the calcium-binding 
proteins MRP8/S100A8 and MRP14/S100A9, forms around 
60% of the cytosolic protein in neutrophil granulocytes and 
is also found in monocytes and the early differentiation stages 
of macrophages. 23 MRP8/S100A8 and MRP14/S100A9 are 
thought to play a role in the innate immune response and to 
function as damage-associated molecular patterns. Fecal cal-
protectin is typically an excellent marker of intestinal inflam-
mation, likely because inflammation is accompanied by 
increased translocation of calprotectin-containing granulocytes 
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into the intestinal mucosa and thus secretion of calprotectin 
into the gut lumen. 24 A number of studies have indicated that 
determination of fecal calprotectin levels can aid in diagnosis 
of inflammatory bowel disease and that there is a correlation 
between fecal calprotectin levels and the degree of inflamma-
tory bowel disease clinical activity. 24, 25 It is possible that the 
lesions and sequelae induced in intestinal schistosomiasis may 
increase fecal calprotectin levels, for example when eggs per-
forate the intestinal lining or stimulate inflammatory reactions 
but this remains to be proven. 
 Blood in stool is an obvious general marker of intestinal mor-
bidity. Even small amounts of blood in the feces, known as fecal 
occult blood (FOB), can be indicative of intestinal pathologic 
changes, for example, colorectal cancer. This finding has led to 
the development of several point-of-care rapid tests for FOB, 
and a recent Cochrane review reports that screening by using 
FOB tests can lead to a modest reduction in colorectal cancer–
associated mortality because positive cases can be detected in 
a more timely fashion. 26 Despite the widespread availability 
of FOB tests and the fact that  S. mansoni eggs perforate the 
intestinal muscosa and cause a small release of blood into the 
bowel, few studies have investigated whether FOB can be used 
as a direct marker of schistosomiasis morbidity. Nevertheless, 
there is some evidence to suggest that there is an association 
between schistosomiasis infection and FOB, although tests 
used show differing sensitivities and recent developments in 
FOB tests have increased detection limits. 27, 28 
 In this study, we determined whether fecal calprotectin 
levels or FOB are associated with intestinal schistosomiasis 
infection and if they could be used in the field as indicators of 
morbidity. To assess this possibility, we screened a population 
of young children (early stage pathology) and mothers (late 
stage pathology) living in lakeshore communities in Uganda 
endemic for  S. mansoni infection. 
 METHODS 
 Study participants and treatment.  This study was carried out 
as part of the Schistosomiasis in Mothers and Infants project, 
a cohort study that is ongoing in six lakeshore communities in 
Uganda to investigate the infection dynamics of  S. mansoni 
and develop better control strategies for younger children. 
The main cohort consists of 333 mothers and 572 young 
children who live in three villages in Buliisa District on Lake 
Albert (Bugoigo, Walukuba, and Piida) and 333 mothers and 
639 young children from three villages in Mayuge District on 
Lake Victoria (Bugoto, Bukoba, and Lwanika). The data used 
for this study were obtained during baseline epidemiologic 
surveys in April and June 2009. Data were also included from 
a pilot study involving 60 mothers and 116 young children 
living in Kayanja and Walumbe in Mayuge District on Lake 
Victoria. 19 Location of study districts are shown in  Figure 1 . 
Numbers of children and mothers questioned and tested 
for fecal occult blood and calprotectin on Lakes Albert and 
Victoria are shown in  Figure 2 . 
 At baseline all participants were treated with praziquan-
tel (for schistosomiasis) and albendazole (for soil-transmitted 
helminths). For younger/smaller children (less than two years 
of age), praziquantel tablets were crushed and mixed with 
orange juice and sugar before administration by spoon-feed-
ing. They also received a chewable orange flavored half-tablet 
of albendazole. 
 Questionnaires.  Each mother was interviewed were inter-
viewed in the local language by a field assistant to ascer-
tain whether she or her children had any history of blood 
in stool, diarrhea, or abdominal pain. Results were used to 
generate binary variables (negative or positive responses). 
These variables were combined to produce one new binary 
variable (blood in stool and diarrhea and abdominal pain). 
Subsequently, the questionnaire results were combined with 
the FOB results to generate four additional variables. 
 Human calprotectin enzyme-linked immunosorbent assay. 
 The human calprotectin enzyme-linked immunosorbent assay 
(ELISA) was conducted in Kayanja and Walumbe (Mayuge 
District) and Bugoigo (Buliisa District). In Kayanja and 
Walumbe, all available stool samples, which there was to time 
process, were tested. In Bugoigo, a random selection of egg-
positive and egg-negative stool samples were tested. Overall, 
72 egg-negative and 69 egg-positive stool samples were 
successfully tested. 
 Stool samples (one sample per person) were processed 
in the field within 24 hours of collection. Stool was passed 
through a 212-µm sieve, and 100 mg of sieved stool was 
homogenized in 5 mL of extraction buffer (0.1 M Tris, 0.15 M 
NaCl, 1.0 M urea, 10 mM CaCl 2 , 0.1 M citric acid monohy-
drate, and 5 g/L of bovine serum albumin). Samples were cen-
trifuged at 10,000 ×  g for 20 minutes, and supernatants were 
then used in the ELISA, which was carried out by using the 
Human Calprotectin ELISA Test Kit (Hycult Biotechnology 
B.V., Uden, The Netherlands) according to the manufacturer’s 
instructions. 
 Absorbance was read at 450 nm by using an LT-4000 
microplate reader (Labtech International Ltd., East Sussex, 
United Kingdom), and mean absorbance was calculated 
for each set of duplicate standards, samples, and negative 
controls. Using Logger Pro version 3.8.2 software (Vernier 
 Figure 1.  Locations of the study sites in Uganda. 1 = location of 
the surveyed villages in Buliisa District on Lake Albert, and 2 = loca-
tion of the villages in Mayuge District on Lake Victoria. 
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Software and Technology, Beaverton, OR), we generated 
a standard curve for each set of standards. This curve was 
used to determine the concentration of calprotectin in each 
stool sample, taking into account the relevant dilution fac-
tor. Using the recommended dilutions of stool samples, we 
determined that the minimum concentration of calprotec-
tin that could be detected in stool with this assay is 65 µg/g. 
The calprotectin concentration data were categorized to pro-
duce a binary variable (calprotectin negative and calprotec-
tin positive). 
 Fecal occult blood tests.  The FOB tests were carried out 
on a random sample (because of a limited supply of tests) of 
persons in the cohort by using the Instalert One Step Fecal 
Occult Blood Test Device (Innovacon, Inc., San Diego, CA) 
according to the manufacturer’s instructions. One fresh stool 
sample was tested per person. The specimen collection stick 
was stabbed into the stool sample at three sites. The stick was 
placed into a specimen collection tube, the cap was screwed on 
tightly, and the tube was shaken vigorously to mix the sample 
and extraction buffer. Two drops of the homogenate were 
then transferred to the specimen well of the FOB test device. 
Results were read after five minutes. Results were classified as 
negative (–), trace, weak positive (+), medium positive (++), 
and strong positive (+++). 
 Detection of intestinal schistosomiasis and soil-transmitted 
helminths.  Parasitologic diagnosis of  S. mansoni and soil-
transmitted helminths ( Trichuris trichiura ,  Ascaris lumbricoides , 
and hookworms) was performed in the field by using two 
stool samples collected on consecutive days and double Kato-
Katz thick smears (2 × 41.7 mg of stools) for each mother 
and child. Samples were inspected by microscopy. 29 Results 
were expressed as mean egg count per gram (epg) of feces. 
The  S. mansoni results were categorized as light (< 100 
epg), medium (100–400 epg), and high (> 400 epg) intensity. 
Similarly, the hookworm,  T .  trichiura , and  A .  lumbricoides 
infection intensities were classified according to World Health 
Organization recommendations. 30 
 Statistical analysis.  Data were entered into a spreadsheet 
by using Microsoft (Redmond, WA) Excel 2004 for Mac (ver-
sion 11.5.6) and were analyzed by using Stata version 11.0 
(StatCorp, College Station, TX) and R version 2.8.1 ( http://
cran.r-project.org/bin/windows/base/ ). Age data were cate-
gorized for children (< 2, 2–4, > 4 years of age) and mothers 
(< 25, 25–35, and > 35 years of age). For schistosomiasis infec-
tion intensity values, the geometric mean of Willams (GM W ) 
and the arithmetic mean of positive samples (AM POS ) were 
chosen as the measures of central tendency because of the 
over-dispersion present in the data. Ninety-five percent con-
fidence intervals (CIs) for GM W were calculated according to 
the procedure of Kirkwood and Sterne. 31 
 To determine whether there was an association between 
 S. mansoni infection and the presence of calprotectin in stool, 
logistic regression was carried out by using the calprotectin 
binary variable as the response variable and schistosomia-
sis infection as the explanatory variable. Logistic regression 
analysis could not be carried out when cut-offs of 100 µg/g or 
150 µg/g were used because there were small numbers in some 
categories. Therefore, the Fisher exact test was used to assess 
associations. 32 
 For analysis of the association between FOB and schisto-
somiasis infection, FOB results were reclassified as a binary 
variable in which negative and trace results were combined 
into one category (negative) and all positive results were com-
bined into the other category (positive). The FOB binary vari-
able was used as the response variable and schistosomiasis 
infection (either as a binary variable or categorized as light, 
medium, and heavy infection) was used as the explanatory 
variable in logistic regression analysis. 
 To assess associations between a history of blood in stool, 
diarrhea or abdominal pain (and the combination of these) 
 Figure 2.  Numbers of children and mothers tested for fecal occult blood and calprotectin, and questioned about blood in stool, diarrhea, 
and abdominal pain on Lakes Albert and Victoria in Uganda. The percentages of those examined who were positive for  Schistosoma mansoni are 
shown in parentheses. Calprotectin analysis was not carried out separately for each lake system; only total numbers of mothers and children tested 
are shown. 
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with schistosomiasis infection, logistic regression analysis 
was carried out by using the questionnaire variables as the 
response variables and schistosomiasis infection as the explan-
atory variable. Similar analysis was carried out to determine 
whether there was an association between the combined FOB/
questionnaire variables and schistosomiasis infection. 
 During the analysis of FOB, calprotectin, and question-
naire data, children and mothers were considered separately. 
Additionally, stepwise analysis was performed to assess the 
effect of potential confounders including village, age, sex, and 
hookworm infection on all models, and comparison between 
models was performed by using likelihood ratio tests. 
 Ethical approval and informed consent.  The London School 
of Hygiene and Tropical Medicine, London, United Kingdom 
(application no. LSHTM 5538·09) and the Ugandan National 
Council of Science and Technology granted ethical approval 
for this study. All participating mothers gave informed consent 
in writing or by fingerprint (in cases of illiteracy) on behalf of 
themselves and their children. 
 RESULTS 
 The mean age of the children was 3.0 years (age range = 4 
months to 6.5 years) and that of the mothers was 28.9 years (age 
range = 15–70 years). In children, the female to male ratio was 
0.95. The overall  S. mansoni infection prevalence levels were 
27.2% in children (GM W = 1.90, 95% CI = 1.61–2.21; AM POS = 
47.62 epg, 95% CI = 40.37–56.17; maximum value = 5,749 
epg) and 47.6% in mothers (GM W = 6.24, 95% CI = 5.11–7.58; 
AM POS = 188.88 epg, 95% CI = 147.78–229.98; maximum value = 
3,537 epg).  Ascaris lumbricoides and  T .  trichiura infection 
prevalence levels were low, and 9.9% of children and 32.6% of 
mothers were infected with hookworms ( Table 1 ). 
 Self-reported symptoms.  Overall, 43.7% of children and 
46.9% of mothers reported a history of blood in stool, 78.7% of 
children and 73.4% of mothers reported a history of diarrhea, 
and 70.5% of children and 79.6% of mothers reported abdom-
inal pain. In children, there was evidence for an association 
between intestinal schistosomiasis infection and any symptom/
combination of symptoms apart from abdominal pain on its 
own ( Table 2 ). In contrast, there was no association between 
schistosomiasis and any of the reported symptoms in mothers. 
 Calprotectin ELISA.  The calprotectin ELISA was conducted 
with fresh stool samples from 58 mothers and 83 children. In 
this subset of mothers and children, the prevalence levels of 
schistosomiasis were 66.0% and 41.0%, respectively. Overall 
26.5% of children and 13.8% of mothers had detectable 
calprotectin (> 65 µg/g) in their stool. The maximum fecal 
calprotectin concentration was 812 µg/g in children and 367 
µg/g in mothers. There was little evidence for an association 
between a calprotectin-positive result and schistosomiasis 
infection in children (odds ratio [OR] = 1.08, 95% CI = 0.40–
2.95,  P = 0.881). In mothers, an inverse relationship between a 
calprotectin-positive result and schistosomiasis infection (OR = 
0.17. 95% CI = 0.03–0.94,  P = 0.043) was found. If published 
cut-off values of 100 µg/g or 150 µg/g were used, there was 
no association between  S. mansoni infection and an increased 
level of fecal calprotectin in children (100 µg/g:  P = 0.414; 150 
µg/g:  P = 0.598), and only a marginally significant association 
in mothers (100 µg/g:  P = 0.162; 150 µg/g:  P = 0.075). 25 
 Fecal occult blood.  The FOB tests were conducted for 814 
children and 448 mothers. On the basis of the results of this 
test, 36.0% of children and 40.9% of mothers had detectable 
blood in their stool. When FOB test results were plotted against 
 S. mansoni infection intensity, there was an obvious positive 
correlation for children and mothers ( Figure 3 ). Logistic 
regression analysis showed that there was a strong association 
between FOB and schistosomiasis infection in children 
(OR = 2.30, 95% CI = 1.57–3.35,  P < 0.0001) and mothers 
(OR = 1.95. 95% CI = 1.24–3.07,  P = 0.004), and heavier 
 S. mansoni infections were more strongly associated with FOB 
( Table 3 ). When data were analyzed separately for each lake, 
 Table 1 
 Prevalence levels of  Schistosoma mansoni , STH infections, and morbidity indicators, Uganda * 
Characteristic Organism or factor Intensity of infection Children, % (95% CI) Mothers % (95% CI)
Schistosomiasis  S. mansoni Any 27.2 (24.8–29.7) 47.6 (43.9–51.2)
Light 18.7 (16.6–20.9) 29.2 (25.9–32.7)
Medium 6.0 (4.8– 7.5) 12.7 (10.3–15.3)
Heavy 2.5 (1.7–3.5) 5.7 (4.1–7.7)
STHs  Ascaris lumbricoides Any 0.2 (0.05–0.7) 0.28 (0.03–1.0)
 Trichuris trichiura Any 1.6 (1.0–2.5) 2.2 (1.3–3.6)
Hookworm Light 9.8 (8.2–11.6) 30.5 (27.1–34.0)
Medium/heavy 0.08 (0.002–0.4) 2.1 (1.2–4.4)
Morbidity indicators Calprotectin 0 mg/g 73.5 (62.7–82.6) 86.2 (74.6–93.9)
< 150 mg/g 12.1 (5.9–21.0) 5.2 (1.1–14.4)
> 150 mg/g 14.5 (7.7–23.9) 8.6 (2.9–19.0)
FOB – 64.0 (60.6–67.3) 59.2 (54.4–63.7)
Trace 15.2 (12.8–17.9) 18.8 (15.2–22.7)
+ 11.4 (9.3–13.8) 12.1 (9.2–15.4)
++ 5.5 (4.1–7.3) 6.3 (4.2–8.9)
+++ 3.8 (2.6–5.4) 3.8 (2.2–6.0)
 *  CI = confidence interval determined using the exact method 47 ; STH = soil-transmitted helminthes; FOB = fecal occult blood. 
 Table 2 
 Association between questionnaire responses and  Schistosoma man-
soni infection in children, Uganda * 
Response No.
% 
Positive * 
OR (95% confidence 
interval)  P 
Blood in stool 1,169 43.7 2.06 (1.59–2.67) < 0.0001
Diarrhea 1,238 78.7 2.55 (1.12–2.43) 0.011
Abdominal pain 1,286 70.5 1.35 (0.98–1.85) 0.066
Blood in stool and diarrhea 
and abdominal pain 1,119 35.2 1.43 (1.07–1.93) 0.017
 *  Percentage of persons who reported a history of the relevant sign or symptom. 
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FOB was associated with schistosomiasis infection in children 
near Lake Albert (OR = 3.27, 95% CI = 1.43–7.43,  P = 0.005) 
and Lake Victoria (OR = 1.75, 95% CI = 1.07–2.87,  P = 0.025) 
but only in mothers near Lake Victoria (OR = 2.31, 95% 
CI = 1.39–3.85,  P = 0.001). In contrast, there was no association 
between FOB and hookworm infection ( Table 3 ). 
 In an attempt to further explore the association between 
FOB test results and schistosomiasis infection, we combined 
questionnaire results with FOB results and the relationship 
with schistosomiasis was investigated. In children and moth-
ers, there was no improvement in the association, although 
in some instances, the OR increased slightly. This finding was 
accompanied by an expansion of the CIs. 
 DISCUSSION 
 We report the results of an investigation designed to iden-
tify markers that could be used in a field situation to assess 
morbidity associated with intestinal schistosomiasis in young 
children and mothers in Uganda. These age classes poten-
tially represent early and late stages of morbidity. We found 
that fecal calprotectin is not a suitable morbidity indicator 
 Figure 3.  Fecal occult blood (FOB) (negative, weak positive, and strong positive) and  Schistosoma mansoni infection intensity (negative, light 
infection, and medium/heavy infection), Uganda. Column widths represent a ratio of 80:11:10 of children with negative, weak positive, and strong 
positive FOB results and a ratio of 39:6:5 of mothers with negative, weak positive, and strong positive FOB results. 
 Table 3 
 Association between FOB and  Schistosoma mansoni infection, Uganda * 
Children Mothers
Infection No. % FOB positive OR (95% CI)  P † No. % FOB positive OR (95% CI)  P † 
 S. mansoni 
Negative 627 17.4 1.00 (–) – 274 17.5 1.00 (–) –
Positive 175 32.6 2.30 (1.57–3.35) < 0.0001 174 29.3 1.95 (1.24–3.07) 0.004
Light infection 125 20.8 1.25 (0.77–2.01) 0.364 123 22.0 1.32 (0.78–2.25) 0.306
Medium infection 36 52.8 5.31 (2.67–10.6) < 0.0001 37 51.3 4.96 (2.41–10.2) < 0.0001
Heavy infection 14 85.7 28.5 (6.29–129) < 0.0001 14 35.7 2.52 (0.80–7.92) 0.115
Hookworm
Negative 690 20.9 1.00 (–) – 241 22.0 1.00 (–) –
Positive 112 19.6 0.93 (0.56–1.53) 0.776 207 22.2 1.01 (0.65–1.59) 0.953
 *  FOB = fecal occult blood; OR = odds ratio; CI = confidence interval. 
 †  By Wald test. 
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for intestinal schistosomiasis. Conversely, a self-reported his-
tory of blood in stool or diarrhea showed a positive associa-
tion with schistosomiasis infection in children. In addition, 
FOB tests show particular promise, especially for assessment 
of morbidity in young children. 
 A number of studies have investigated whether question-
naires enquiring about current or past experience of symp-
toms such as blood in stool and diarrhea can be used for 
individual assessment of morbidity or to determine which 
communities are at high risk of disease. Overall blood in stool 
has been found to be most strongly associated with schistoso-
miasis infection but the results were variable with a diagnos-
tic sensitivity of 7–66% and specificity of 54–96%. 21 We found 
that a history of blood in stool or diarrhea was associated with 
 S. mansoni infection in children but not in mothers. However, 
if children near the two lakes were considered separately, the 
evidence for a relationship between positive questionnaire 
responses and  S. mansoni infection was much weaker, indicat-
ing that questionnaire data may only be useful for assessing 
morbidity when studying large numbers of young children. 
The fact that questionnaire data were not particularly reli-
able as morbidity indicators is not surprising. Symptoms such 
as blood in stool and diarrhea are not specific for intestinal 
schistosomiasis and can be caused by a number of different 
infections. In addition, the data depend on the mother’s recall 
of her own symptoms and those of her children, which may be 
imperfect. In contrast, self-reported blood in urine is found to 
be commonly associated with urinary schistosomiasis, caused 
by S.  haematobium , in schistosomiasis-endemic areas. 33– 35 
 No positive association between fecal calprotectin and 
schistosomiasis infection was observed in children or mothers 
when we used a range of cut-off values, which indicated that 
human calprotectin is unlikely to be suitable as a morbidity 
marker for intestinal schistosomiais. This finding is surprising 
given the fact that inflammatory processes in the intestines 
play an important role in schistosomiasis progression, and that 
MRP8 and MRP14 have been detected in mononuclear cells 
at the periphery of granulomas in mice infected with  S. man-
soni . 36 Chronic inflammation associated with  S. mansoni eggs 
appears to involve recruitment of eosinophils rather than neu-
trophils, which may explain why there is no detectable increase 
in fecal calprotectin in infected persons. 13 
 Nine children but no mothers had a calprotectin concen-
tration outside the ranges previously reported in healthy per-
sons. 37 The increased calprotectin levels observed in some 
children may reflect underlying intestinal pathologic changes 
or could lie within the normal range for children from Africa 
because our study is the first to investigate fecal calprotectin 
levels in a population in sub-Saharan Africa. Increased cal-
protectin levels are observed in newborn and breast-feeding 
infants, 38, 39 but because the youngest child with an increased 
calprotectin level in our study is one year of age, this finding is 
unlikely to be relevant to our results. 
 Even if a correlation were seen between fecal calprotec-
tin and schistosomiasis infection, there would be a number 
of difficulties associated with widespread deployment of the 
calprotectin ELISA in the field. First, the ELISA is expen-
sive. Taking into account standards, controls and replicates, we 
determined that the cost per person would be approximately 
$20. Second, a reliable cold chain for storage of the kit compo-
nents and an ELISA plate reader are required, thus necessi-
tating an on-site power source. Third, the protocol is relatively 
complicated for a field-based setting and requires well-trained 
staff. Recently, rapid tests for fecal calprotectin have been 
developed, which may provide a viable alternative to ELISAs 
in field-based studies but are unlikely to be further informa-
tive in this context. 40, 41 
 Our data show a strong association between  S. mansoni 
infection and FOB in mothers near Lake Victoria and in chil-
dren near both lakes. A variety of infections and intestinal 
conditions can also cause occult blood in feces, including para-
sitic worms and colorectal cancer. Obviously, colorectal can-
cer is not an issue for young children and is likely to account 
for only a small fraction of FOB-positive results in moth-
ers. Interestingly, there was no association between hook-
worm infection and FOB in this cohort, although there was 
a low prevalence of hookworm infection near Lake Albert 
and hookworm infection intensities were generally low near 
Lake Victoria. Consistent with our results, Kanzaria and oth-
ers found that persons with higher intensity hookworm infec-
tions were no more likely to be fecal occult blood positive than 
those with low intensity infections or no infection, although 
they were more likely to be anemic. 28 
 We found few  Ascaris and  Trichuris infections in this study. 
Previous work has shown that levels of  Strongyloides stercora-
lis and  Entamoeba histolytica in these communities were also 
low (Sousa-Figueiredo JC, unpublished data). 42 Of note, when 
the same FOB tests were used in Zanzibar where prevalence 
levels of soil-transmitted helminths were moderate to high, 
the prevalence of FOB-positive results was only 7% in chil-
dren and 14% in mothers. 43 Nevertheless, we cannot entirely 
exclude the possibility that there is another infectious agent 
present in our study population, which correlates with schis-
tosomiasis infection and FOB. The FOB test used in this sur-
vey uses a double-antibody sandwich assay and is specific for 
human hemoglobin. Thus, test results were not influenced by 
diet but may have been affected by blood released from other 
lesions (e.g., hemorrhoids) or through contamination of fecal 
material with menstrual blood in mothers. 
 There are several possible explanations for the stronger 
association between FOB and  S. mansoni infection in moth-
ers near Lake Victoria compared with those near Lake Albert. 
First, there is some genotypic partitioning in the  S. mansoni 
parasite between Lake Albert and Lake Victoria, which may 
be associated with differences in the morbidity induced by 
the parasite. 44 Second, there are tribal differences in persons 
near the two lakes, which may lead to differences in immune 
responses to  Schistosoma eggs. Third, near Lake Albert, moth-
ers may have other infections which could lead to FOB and 
mask the relationship with schistosomiasis. Fourth, infection 
dynamics can influence morbidity. It is known that immune 
responses to schistosomiasis are down-modulated over time 
and the number of eggs produced by adult worms can also 
vary. Thus, more recent infections may produce greater intesti-
nal bleeding than long-standing infections. 13 
 The utility of FOB tests for diagnosis or assessment of 
morbidity associated with intestinal schistosomiasis has been 
investigated previously but with tests of differing sensitivities. 
In China, no relationship was observed between FOB and the 
presence or intensity of  S. japonicum infection. 45 In contrast, 
studies in Brazil and Zimbabwe showed a positive correlation 
between intensity of  S. mansoni infection and percentage of 
FOB-positive stools. 27, 46 Similarly, in the Philippines, persons 
with heavy  S. japonicum infections were 3.5 times more likely 
1054 BETSON AND OTHERS
to be FOB positive than those with no or light to moderate 
infections. 28 To our knowledge, the present study is the first to 
use an immunochemistry-based test to assess the association 
between  S. mansoni infection and FOB and the first to show a 
positive relationship between schistosomiasis infection/inten-
sity and FOB in young children. 
 The FOB test used for this study is well suited to field con-
ditions. All components can be stored at room temperature 
and the test is rapid and simple, enabling hundreds of stool 
samples to be tested per day. The only disadvantage is that it 
is relatively expensive, costing approximately $1.70 per per-
son. Future follow-ups of the cohort will hope to ascertain if 
FOB can track the dynamics of morbidity after treatment with 
praziquantel. If the test meets this expectation, it could play 
an important role in assessing patterns of morbidity reduc-
tion associated with ongoing and future national control 
programs. 
 Fecal calprotectin was not informative in assessment of the 
morbidity associated with intestinal schistosomiasis. Although 
self-reported abdominal symptoms may be of use for screen-
ing large populations of young children, they are far less useful 
on a smaller scale. In contrast, fecal occult blood, as assessed 
by using an immunochemistry-based rapid test, is strongly 
associated with prevalence and intensity of intestinal schisto-
somiasis infection in young children in Uganda. Thus, this test 
should prove to be a useful tool for community-level deter-
mination of intestinal morbidity in young children in sub-
Saharan Africa and hopefully for assessment of reductions in 
morbidity in response to mass chemotherapy. 
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